Traws Pharma Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Traws Pharma Advances Oral COVID-19, Monthly Flu Antiviral Toward Next Milestones
Traws Pharma Reports Final Phase 2a Results for Ratutrelvir in COVID-infected Subjects, Showing Fewer Treatment-Related Adverse Events and No Viral Rebounds Versus PAXLOVID®
Traws Pharma Reports Final Phase 2a COVID-19 Data, Advances Influenza Candidate
Traws Pharma Enters $50M Committed Equity Purchase Agreement With Roth Principal Investments; May Issue And Sell Up To 135,135,135 Shares Of Common Stock
Traws Pharma Enters Stock Purchase Agreement With Roth Principal Investments On Oct 23, 2026; May Sell Up To $50M In Common Stock To Roth Principal Investments
HC Wainwright & Co. Reiterates Neutral on Traws Pharma, Maintains $1 Price Target
Traws Pharma shares rise after Q2 loss comes in better than expected
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
Traws Pharma Q2 EPS $(0.16) Beats $(0.34) Estimate
Traws PharmaFiles Prospectus For Mixed Shelf Offering Of Up To ~$139.2M
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
Traws Pharma Announces That An Updated Toxicology Data Package Is Being Developed In Response To The UK MHRA's Information Requirements For Planned Testing Of Tivoxavir Marboxil In A Phase 2a Human Influenza Challenge Study
HC Wainwright & Co. Downgrades Traws Pharma to Neutral, Announces $1 Price Target
Ladenburg Thalmann Downgrades Traws Pharma to Neutral
Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study
Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study
Why Did TRAW Stock Slump 28% After Hours?
Traws Pharma Provides Regulatory Update on Influenza Program
Traws Pharma Defers Planned Phase 2a Influenza Study Of Tivoxavir Marboxil After Negative UK MHRA Review; Cash Runway Extends To Q1 2027; Advancing Alternative Influenza Antiviral Candidates
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.